HomeCompareINRLF vs SBUX

INRLF vs SBUX: Dividend Comparison 2026

INRLF yields 63.90% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INRLF wins by $629.8K in total portfolio value
10 years
INRLF
INRLF
● Live price
63.90%
Share price
$3.13
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$787.3K
Annual income
$193,029.75
Full INRLF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — INRLF vs SBUX

📍 INRLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINRLFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INRLF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INRLF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INRLF
Annual income on $10K today (after 15% tax)
$5,431.31/yr
After 10yr DRIP, annual income (after tax)
$164,075.29/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, INRLF beats the other by $108,111.18/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INRLF + SBUX for your $10,000?

INRLF: 50%SBUX: 50%
100% SBUX50/50100% INRLF
Portfolio after 10yr
$472.4K
Annual income
$129,434.94/yr
Blended yield
27.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

INRLF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-1.2
Piotroski
3/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INRLF buys
0
SBUX buys
0
No recent congressional trades found for INRLF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINRLFSBUX
Forward yield63.90%2.75%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$787.3K$157.5K
Annual income after 10y$193,029.75$65,840.13
Total dividends collected$660.4K$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: INRLF vs SBUX ($10,000, DRIP)

YearINRLF PortfolioINRLF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$17,090$6,389.78$11,107$407.21+$6.0KINRLF
2$28,492$10,205.59$12,512$626.87+$16.0KINRLF
3$46,387$15,901.41$14,366$978.69+$32.0KINRLF
4$73,830$24,195.53$16,929$1,557.50+$56.9KINRLF
5$114,988$35,990.20$20,658$2,543.80+$94.3KINRLF
6$175,424$52,386.69$26,406$4,302.22+$149.0KINRLF
7$262,396$74,691.78$35,877$7,622.00+$226.5KINRLF
8$385,177$104,413.37$52,741$14,352.64+$332.4KINRLF
9$555,383$143,243.74$85,676$29,243.03+$469.7KINRLF
10$787,290$193,029.75$157,513$65,840.13+$629.8KINRLF

INRLF vs SBUX: Complete Analysis 2026

INRLFStock

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Full INRLF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this INRLF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INRLF vs SCHDINRLF vs JEPIINRLF vs OINRLF vs KOINRLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.